Login to Your Account

Clinic Roundup

Tuesday, April 3, 2012

• Oncolytics Biotech Inc., of Calgary, Alberta, completed enrollment in the first stage of its Phase III trial examining Reolysin in combination with paclitaxel and carboplatin in 80 patients with platinum-refractory head and neck cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription